DalsnaFinance

Bioage Labs Inc $BIOA

Health Care

Russell 2000

Create a scorecard

$9.59

+0.09 (+0.95%)

As of Sep 5, 2026, 10:32 AM EDT

Price history

Loading chart…

Bioage Labs Inc (BIOA) is trading up at $9.59 (+0.95%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.

IPO: September 26, 2024 · $18.00 offering · NASDAQ · View IPO details →

Recent News (9)

BioAge Labs to Present at Upcoming Investor Conferences GlobeNewswire · 02 Sep 2026 EMERYVILLE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates fo…
Canada's Drug Agency issues final positive recommendation supporting public reimbursement of Leqembi® PR Newswire · 01 Sep 2026 STOCKHOLM, Sept. 1, 2026 /PRNewswire/ -- BioArctic AB's (publ) (STO: BIOA B) partner Eisai announced today that Canada's Drug Agency (CDA-AMC) has issued a final recommendation supporting public reimb…
Canada's Drug Agency issues final positive recommendation supporting public reimbursement of Leqembi® PR Newswire · 01 Sep 2026 STOCKHOLM, September 1, 2026 /PRNewswire/ -- BioArctic AB's (publ) (STO: BIOA B) partner Eisai announced today that Canada's Drug Agency (CDA-AMC) has issued a final recommendation supporting public r…
Number of shares and votes in BioArctic AB (publ) as of August 31, 2026 PR Newswire · 31 Aug 2026 STOCKHOLM, Aug. 31, 2026 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company issued 20,200 Class B shares during August for delivery of shares to participan…
Number of shares and votes in BioArctic AB (publ) as of August 31, 2026 PR Newswire · 31 Aug 2026 STOCKHOLM, Aug. 31, 2026 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company issued 20,200 Class B shares during August for delivery of shares to participan…
Leqembi Iqlik® for initiation treatment launched in the US PR Newswire · 24 Aug 2026 STOCKHOLM, Aug. 24, 2026 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai today announced that lecanemab-irmb subcutaneous injection (US brand name: Leqembi Iqlik®), whic…
Leqembi Iqlik® for initiation treatment launched in the US PR Newswire · 24 Aug 2026 STOCKHOLM, Aug. 24, 2026 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai today announced that lecanemab-irmb subcutaneous injection (US brand name: Leqembi Iqlik®), whic…
Sales of Leqembi® totaled 29.3 billion yen in the second quarter 2026 PR Newswire · 29 Jul 2026 STOCKHOLM, July 29, 2026 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi for the second quarter 2026, in conju…
Sales of Leqembi® totaled 29.3 billion yen in the second quarter 2026 PR Newswire · 29 Jul 2026 STOCKHOLM, July 29, 2026 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi for the second quarter 2026, in conju…

More Health Care stocks

Browse all companies →